Jump to: navigation, search

B-cell acute lymphoblastic leukemia - historical

1,242 bytes added, 16:00, 2 January 2019
Maintenance after upfront therapy
# Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, George SL, Pui CH. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia: identification of a relation between concentration and effect. N Engl J Med. 1986 Feb 20;314(8):471-7. [ link to original article] [ PubMed]
=Late intensification=
==POMP {{#subobject:31219|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|[[#top|back to top]]
POMP: '''<u>P</u>'''urinethol (Mercaptopurine), '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rednisone
===Regimen {{#subobject:93b1b3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|[ Bodey et al. 1976]
| style="background-color:#ffffbe" |Non-randomized, <20 pts
''Note: POMP is still used in maintenance settings; this is marked historic because it is late intensification.''
*[[Mercaptopurine (Purinethol)]]
*[[Vincristine (Oncovin)]]
*[[Methotrexate (MTX)]]
*[[Prednisone (Sterapred)]]
# Bodey GP, Freireich EJ, Gehan E, McCredie KB, Rodriguez V, Gutterman J, Burgess MA. Late intensification therapy for acute leukemia in remission: chemotherapy and immunotherapy. JAMA. 1976 Mar 8;235(10):1021-5. [ link to original article] [ PubMed]
=Maintenance after upfront therapy=
LookupUsers, editors, emailconfirmed

Navigation menu